Reports Q1 revenue $8.982M, consensus $1.98M. “We had a great first quarter of launch and are highly encouraged by physician enthusiasm for AUCATZYL in the U.S. We believe this speaks to the product profile and significant unmet need for patients,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “Building on that momentum in the U.S., we recently obtained marketing authorization from the UK’s MHRA, and we are working in collaboration with National Institute for Health and Care Excellence to bring this much-needed therapy to patients in the UK. Our goal to expand into new markets is underpinned by our proprietary manufacturing and commercial infrastructure which has positioned us for strong execution.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRA
- Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA
- Autolus Therapeutics: Promising Clinical Results and Strategic Initiatives Support Buy Rating
- Autolus Therapeutics: Promising Developments in Lupus Nephritis Drive Buy Rating
- Autolus Therapeutics to Present R&D Update April 23
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue